Cancer Immunotherapy

Prof Haiyan LIU
Professor and Principle Investigator
Institutes of Biology and Medical Sciences
Soochow University, P. R. China

Abstract
Immunotherapy has become a promising strategy for cancer therapy. In the past several decades, numerous treatment modalities have been developed to harness the immune system against cancer, including antibody-based therapy, adoptive cell therapy and therapeutic vaccines. The approval of the first therapeutic cancer vaccine by U.S. Food and Drug Administration and the recent success of checkpoint antibody blockade, as well as the CD19 CAR-T cell approach pave the way for future more robust and durable cancer immunotherapies. A synopsis of the history and current state of the major aspects of cancer immunotherapy will be presented. The obstacles for effective targeted therapy will be discussed in order to outline the future directions for optimization of cancer immunotherapy. You are encouraged to read the provided papers and prepare to discuss during the seminar on this exciting topic.

Selected Publications